Biomarkers for glioblastoma multiforme: status quo

BACKGROUND: Glioblastoma (GBM) is the most frequent and most malignant central nervous system (CNS) tumor. GBM shows poor prognosis with a median overall survival of 14.6 months, despite current surgical and adjuvant therapies. O(6)-methylguanine-DNA methyltransferase (MGMT) methylation is the stron...

Descripción completa

Detalles Bibliográficos
Autores principales: Montano, Nicola, D’Alessandris, Quintino Giorgio, Izzo, Alessandro, Fernandez, Eduardo, Pallini, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Whioce Publishing Pte. Ltd. 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410643/
https://www.ncbi.nlm.nih.gov/pubmed/30873456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410643/
https://www.ncbi.nlm.nih.gov/pubmed/30873456

Ejemplares similares